Bismuth trioxide

We are Bismuth trioxide CAS:1304-76-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Other name: 
Bismuth Oxide

CAS No.: 1304-76-3

Molecular Weight: 465.96
 

Characters: Yellow heavy powder. soluble in acids, insoluble in water, will turn red when heated.
 

Specifications:

Sodium molybdate	A.R.	Technical grade	Electronic grade
Item	Spec.	Spec.	Spec.
Insol. in nitric acid %	≤0.005	≤0.01	≤0.005
Sulphates(SO4)%	≤0.01	≤0.05	≤0.01
Chlorides(Cl) %	≤0.005	≤0.01	≤0.005
Alkali metals and alkaline-earth metals(asSO4)%	≤0.05	≤0.1	≤0.05
Fe%	≤0.002	≤0.005	≤0.002
N%	≤0.003	≤0.05	≤0.003
Cu%	合格	合格	合格
As%	≤0.001	≤0.005	≤0.001
Loss on ignition %	≤1	≤1	≤1

Product Usage: Bismuth oxide can be widely used in inorganic synthesis, electronic ceramics, chemical reagents etc. It is mainly used in the manufacture of ceramic dielectric capacitor, piezoceramics and voltage dependent resistor etc.

Packaging: 25kg cardboard drum, lined with double-layer plastic bag

Storage Precautions: Protect against fire, sunlight, damange or pollution

Related News: The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.143183-03-3 The novel coronavirus has resulted in thousands of confirmed human infections in more than 20 countries, with more than 99 percent of cases in China.2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone CAS:106797-53-9 Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.ÁCIDO BENZOICO 2-FLUORO-3- (TRIFLUOROMETHYL) CAS:115029-22-6 Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.